IL292522A - Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi - Google Patents

Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi

Info

Publication number
IL292522A
IL292522A IL292522A IL29252222A IL292522A IL 292522 A IL292522 A IL 292522A IL 292522 A IL292522 A IL 292522A IL 29252222 A IL29252222 A IL 29252222A IL 292522 A IL292522 A IL 292522A
Authority
IL
Israel
Prior art keywords
cgvhd
substituted
unsubstituted
patient
inhibitor
Prior art date
Application number
IL292522A
Other languages
English (en)
Hebrew (he)
Original Assignee
Pharmacyclics Llc
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc, Univ Minnesota filed Critical Pharmacyclics Llc
Publication of IL292522A publication Critical patent/IL292522A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
IL292522A 2013-12-02 2014-12-02 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi IL292522A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361910944P 2013-12-02 2013-12-02
US201461973178P 2014-03-31 2014-03-31
PCT/US2014/068177 WO2015084857A1 (en) 2013-12-02 2014-12-02 Methods of treating and preventing alloantibody driven chronic graft versus host disease

Publications (1)

Publication Number Publication Date
IL292522A true IL292522A (en) 2022-06-01

Family

ID=53270044

Family Applications (4)

Application Number Title Priority Date Filing Date
IL292522A IL292522A (en) 2013-12-02 2014-12-02 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi
IL315228A IL315228A (en) 2013-12-02 2014-12-02 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi
IL245715A IL245715A0 (en) 2013-12-02 2016-05-18 Methods for the treatment and prevention of chronic graft-versus-host disease prevented using alloantibody
IL276683A IL276683A (en) 2013-12-02 2020-08-12 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL315228A IL315228A (en) 2013-12-02 2014-12-02 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi
IL245715A IL245715A0 (en) 2013-12-02 2016-05-18 Methods for the treatment and prevention of chronic graft-versus-host disease prevented using alloantibody
IL276683A IL276683A (en) 2013-12-02 2020-08-12 Ibrutinib and its uses as a drug for the treatment of inflammatory obstruction of the bronchi

Country Status (14)

Country Link
US (6) US20150157634A1 (enExample)
EP (1) EP3076975A4 (enExample)
JP (5) JP2017501140A (enExample)
KR (2) KR20160085817A (enExample)
CN (2) CN110478353B (enExample)
AU (4) AU2014360758B2 (enExample)
BR (1) BR112016012158A2 (enExample)
CA (2) CA2932255C (enExample)
EA (1) EA201691020A1 (enExample)
IL (4) IL292522A (enExample)
MX (2) MX389020B (enExample)
PH (2) PH12020552048A1 (enExample)
TW (3) TWI743019B (enExample)
WO (1) WO2015084857A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736178A (zh) 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
AU2014339815B2 (en) 2013-10-25 2020-03-26 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
AR102871A1 (es) 2014-12-03 2017-03-29 Pharmacyclics Llc Métodos de tratamiento de fibrosis
ES2863700T3 (es) * 2016-03-22 2021-10-11 Mayo Found Medical Education & Res Uso de inhibidores de ácido graso sintasa para tratar la fibrosis
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
WO2018075888A1 (en) * 2016-10-21 2018-04-26 Regents Of The University Of Minnesota Materials and methods for treating or preventing graft-versus-host-disease
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
US12496303B2 (en) 2020-10-19 2025-12-16 Washington University Conditioning agents for use in allogeneic hematopoietic stem cell transplantation
WO2022119931A1 (en) * 2020-12-01 2022-06-09 City Of Hope Prevention and treatment of graft-versus-host disease (gvhd)
CN116782946A (zh) * 2021-01-30 2023-09-19 百济神州有限公司 使用btk抑制剂治疗慢性活动性抗体介导的排斥的方法
US20240287781A1 (en) 2023-02-28 2024-08-29 Toto Ltd. Wall-mounted flush toilet

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US20060182723A1 (en) * 2005-01-25 2006-08-17 Spellberg Brad J Methods for treating refractory infections in neutropenic individuals
MX2008008642A (es) * 2006-01-13 2008-09-12 Pharmacyclics Inc Inhibidores de las tirosina cinasas y usos de los mismos.
SI2529622T1 (en) * 2006-09-22 2018-06-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2010009342A2 (en) * 2008-07-16 2010-01-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
US8765754B2 (en) * 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
JP2013503204A (ja) * 2009-08-31 2013-01-31 アンプリミューン， インコーポレイテッド Ｂ７−ｈ４融合タンパク質およびその使用方法
US20120071497A1 (en) * 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
NZ753024A (en) * 2010-06-03 2020-08-28 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2013008095A1 (en) * 2011-07-08 2013-01-17 Novartis Ag Novel pyrrolo pyrimidine derivatives
WO2013155347A1 (en) * 2012-04-11 2013-10-17 Izumi Raquel Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
US10722577B2 (en) * 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
CA2898472C (en) * 2013-02-15 2023-03-07 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
AU2014339815B2 (en) * 2013-10-25 2020-03-26 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor

Also Published As

Publication number Publication date
KR20230104754A (ko) 2023-07-10
US20210177854A1 (en) 2021-06-17
US20230100137A1 (en) 2023-03-30
AU2020204276A1 (en) 2020-07-16
CN105939717A (zh) 2016-09-14
JP2025118595A (ja) 2025-08-13
IL276683A (en) 2020-09-30
US20180078558A1 (en) 2018-03-22
CA2932255A1 (en) 2015-06-11
IL315228A (en) 2024-10-01
PH12016501051A1 (en) 2016-08-15
US20250381188A1 (en) 2025-12-18
AU2014360758A1 (en) 2016-06-16
KR20160085817A (ko) 2016-07-18
TW202402295A (zh) 2024-01-16
KR20230104754A9 (ko) 2024-11-15
CA3210338A1 (en) 2015-06-11
AU2024278490A1 (en) 2025-01-09
AU2022203810B2 (en) 2024-10-03
EP3076975A1 (en) 2016-10-12
MX2016006955A (es) 2016-09-07
AU2022203810A1 (en) 2022-06-23
TW201605454A (zh) 2016-02-16
TW202228700A (zh) 2022-08-01
MX2022000209A (es) 2022-02-03
US20150157634A1 (en) 2015-06-11
CA2932255C (en) 2023-10-10
MX389020B (es) 2025-03-20
US20240293409A1 (en) 2024-09-05
TWI743019B (zh) 2021-10-21
CN105939717B (zh) 2019-09-13
CN110478353A (zh) 2019-11-22
JP2017501140A (ja) 2017-01-12
JP2020105181A (ja) 2020-07-09
EA201691020A1 (ru) 2017-01-30
EP3076975A4 (en) 2017-05-03
IL245715A0 (en) 2016-07-31
JP2024072291A (ja) 2024-05-27
AU2014360758B2 (en) 2020-03-26
JP2023029899A (ja) 2023-03-07
CN110478353B (zh) 2022-12-30
BR112016012158A2 (pt) 2017-09-26
WO2015084857A1 (en) 2015-06-11
PH12020552048A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
US20250381188A1 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
AU2023274176B2 (en) Methods of treating and preventing graft versus host disease
HK40086449A (en) Methods of treating and preventing graft versus host disease